Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing InnoCare Pharma Tech Co., Ltd.
About this trial
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
Eligibility criteria
Qualifiers
18 years old to 75 years old;
Unresectable locally advanced or metastatic gastrointestinal tumors or other advanced solid tumors that have failed previous systemic treatment and have been confirmed by histopathology or cytology;
The ECOG physical fitness score is 0 to 1 point.
There is at least one measurable lesion;
Disqualifiers
Other active malignant tumors occurred within 3 years before the first administration of the study drug;
Received the anti-tumor treatment defined by the protocol within the time range before the first administration of the study drug specified in the protocol;
Trial participants with unstable primary CNS tumors or CNS metastases;
Uncontrollable or significant major cardiovascular diseases;
Trial design
Treatments tested in this trial
- ICP-B208
Treatment groups
539 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov